The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors

Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry

(2016) Leslie A. Parsels et al.   CELL CYCLE

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

(2016) Emiliano Calvo et al.   ONCOLOGY

Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading

(2016) Sissel Hauge et al.   Oncotarget

Signaling from Mus81-Eme2-Dependent DNA Damage Elicited by Chk1 Deficiency Modulates Replication Fork Speed and Origin Usage

(2016) Hervé Técher et al.   Cell Reports

CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus

(2015) S.-B. Koh et al.   CANCER RESEARCH

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

(2015) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional Genetic Screen Identifies Increased Sensitivity to WEE1 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways

(2015) M. Aarts et al.   MOLECULAR CANCER THERAPEUTICS

The fork and the kinase: A DNA replication tale from a CHK1 perspective

(2015) Marina A. González Besteiro et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase

(2015) Nandini Sakurikar et al.   Oncotarget

The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases

(2014) Stéphanie Solier et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas

(2013) Jenny M. Kreahling et al.   PLoS One

Essential role for Cdk2 inhibitory phosphorylation during replication stress revealed by a human Cdk2 knockin mutation

(2013) B. T. Hughes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In-solution staining and arraying method for the immunofluorescence detection of γH2AX foci optimized for clinical applications

(2012) Pegah Johansson et al.   BIOTECHNIQUES

Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo

(2012) Laura Carrassa et al.   CELL CYCLE

Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide Consumption

(2012) H. Beck et al.   MOLECULAR AND CELLULAR BIOLOGY

Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination

(2012) M Krajewska et al.   ONCOGENE

Kinase-independent function of checkpoint kinase 1 (Chk1) in the replication of damaged DNA

(2012) J. Speroni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition

(2011) L. A. Parsels et al.   CLINICAL CANCER RESEARCH

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor

(2011) H. Hattori et al.   MOLECULAR CANCER THERAPEUTICS

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication

(2011) C. S. Sorensen et al.   NUCLEIC ACIDS RESEARCH

Development of a Validated Immunofluorescence Assay for  H2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

(2010) R. J. Kinders et al.   CLINICAL CANCER RESEARCH

Enhanced H2AX Phosphorylation, DNA Replication Fork Arrest, and Cell Death in the Absence of Chk1

(2010) Mary E. Gagou et al.   MOLECULAR BIOLOGY OF THE CELL

Chk1 promotes replication fork progression by controlling replication initiation

(2010) E. Petermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE